View : 627 Download: 114
Influence of C Upsilon P2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis
- Title
- Influence of C Upsilon P2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis
- Authors
- Park, Yoon-A; Song, Yu-bin; Yee, Jeong; Yoon, Ha-Young; Gwak, Hye-Sun
- Ewha Authors
- 곽혜선
- Issue Date
- 2021
- Journal Title
- JOURNAL OF PERSONALIZED MEDICINE
- ISSN
- 2075-4426
- Citation
- JOURNAL OF PERSONALIZED MEDICINE vol. 11, no. 7
- Keywords
- losartan; E-3174; C Upsilon P2C9; polymorphism; pharmacokinetics
- Publisher
- MDPI
- Indexed
- SCIE; SCOPUS
- Document Type
- Review
- Abstract
- This study aimed to investigate the influence of C Upsilon P2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used PubMed, the Cochrane Library, EMBASE, and Web of Science, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The data analysis was conducted through Review Manager (RevMan), version 5.3, and R software. We found that healthy volunteers with C Upsilon P2C9*2 or *3 carriers had higher area under the curve (AUC(0-infinity)) of losartan (mean difference (MD) 0.17 mu g.h/mL; 95% confidence intervals (CI): 0.04, 0.29) and lower AUC(0-infinity) of E-3174 (MD -0.35 mu g.h/mL; 95% CI: -0.62, -0.08) than those with C Upsilon P2C9*1/*1. Subjects with C Upsilon P2C9*2 or *3 carriers showed lower maximum concentration (C-max) of E-3174 than those with C Upsilon P2C9*1/*1 (MD -0.13 mu g/mL; 95% CI: -0.17, -0.09). For half-life, subjects with C Upsilon P2C9*2 or *3 carriers had longer half-lives of losartan and E-3174 than those with C Upsilon P2C9*1/*1 (MD 0.47 h; 95% CI: 0.32, 0.61 and MD 0.68 h; 95% CI: 0.44, 0.92, respectively). This meta-analysis suggests that the pharmacokinetics of losartan and E-3174 are associated with the C Upsilon P2C9 polymorphisms
- DOI
- 10.3390/jpm11070617
- Appears in Collections:
- 약학대학 > 약학과 > Journal papers
- Files in This Item:
-
jpm-11-00617-v2.pdf(3.05 MB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML